Hemodynamic profiles of intubated and mechanically ventilated carbon monoxide-poisoned patients during systemic hyperbaric oxygen therapy by unknown
Chateau-Degat et al. BMC Anesthesiology 2013, 13:26
http://www.biomedcentral.com/1471-2253/13/26RESEARCH ARTICLE Open AccessHemodynamic profiles of intubated and
mechanically ventilated carbon monoxide-
poisoned patients during systemic hyperbaric
oxygen therapy
Marie-Ludivine Chateau-Degat1,2,3*, Julien Poitras1,2 and Jacques H Abraini1,4,5Abstract
Background: Carbon monoxide (CO) poisoning can be a life threatening condition. Systemic hyperbaric oxygen
(HBO) therapy is used to induce CO detoxification. However, little is known about the hemodynamic response to
HBO in severely intoxicated patients.
Methods: We retrospectively analyzed the medical records of 6 CO-poisoned patients treated with propofol,
rocuronium bromide, and HBO. The HBO protocol comprised 3 HBO treatments (HBOT1 to HBOT3) within 24 hours.
During all HBO sessions heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse
blood pressure (ΔBP) were measured every five minutes. Non-parametric tests were used to compare data between
HBO sessions.
Results: HR increased significantly as the number of HBOT increased, from 68 beats per minute (bpm) during
HBOT1 to 77 and 86 bpm during HBOT2 and HBOT3, respectively (p < 0.05). In addition, while no significant change
was found for DBP, both SBP and ΔBP showed a transient and significant increase during HBOT2, compared to
HBOT1, that did not return to basal values during HBOT3.
Conclusion: Based on previous studies that have established the respective effects of rocuronium bromide,
propofol, HBO, and CO alone on HR, SBP, and ΔBP, it is concluded that the hemodynamic responses observed in
the present study are likely to be due to CO. If such, given that neither HR nor SBP and ΔBP returned to basal
values by the end of HBOT3, it is suggested that more than 3 HBOT sessions could be necessary to provide full
hemodynamic recovery in CO-poisoned patients.Background
Carbon monoxide (CO) poisoning can be a life threaten-
ing condition that is associated with a long-term increased
risk of mortality in severely intoxicated patients [1,2]. Be-
cause of the ability of oxygen to dissociate carboxyhemo-
globin, high flow normobaric 100 vol% oxygen is used as a
first-line therapy [3,4]. As another therapeutic strategy,
systemic hyperbaric oxygen (HBO) therapy with 100 vol%
oxygen is often used, when available, as a second line* Correspondence: ludivinechateaudegat@me.com
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distribution, and reproduction in any mediumtreatment in moderate to severe CO-poisoned patients to
accelerate and improve the detoxification process [4-6].
However, although previous studies have established the
effects of acute and repetitive HBO on the hemodynamic
parameters of healthy subjects, certain types of patients,
and laboratory animals [7-11], little is known on the
hemodynamic effects of HBO in CO-poisoned patients.
Thus, the purpose of this retrospective study was to assess
the effects of HBO on the hemodynamic parameters of
critically ill CO-poisoned patients.
Methods
Study design
This retrospective study is based on the review of the
medical records of patients admitted for CO poisoningCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Characteristics of patients upon arrival at the
emergency department before first systemic hyperbaric
oxygen treatment
Patient Age Sex CoHb GSC Tn1 Delay Cardiovascular ASA
Comorbidities
#1 52 M 35% 4 0.02 5 h00 CAD II
#2 36 M 37% 6 0.20 5 h45 No I
#3 40 M 26% 9 0.53 5 h00 No I
#4 48 M 55% 3 0.52 5 h00 SSS/PM IV
#5 64 F 50% 3 0.08 3 h45 T2DM IV
#6 63 F 34% 15 0.06 12 h00 HTN III
Values collected in the emergency room before the patient was intubated and
then treated with hyperbaric oxygen (HBOT1); GSC: Glasgow Coma Scale upon
arrival at the emergency department; CoHb: Carboxyhemoglobin (values recorded
before arrival at CSSS Alphonse-Desjardins Hôtel-Dieu de Lévis hospital); Tn1:
troponin 1; Delay: between first primary care by paramedics and HBOT1; CAD:
Coronary artery disease; SSS/PM: Sick sinus syndrome/pacemaker; T2DM: Type 2
diabetes mellitus; HTN: Hypertension. ASA: American Society of Anesthesiology
patient classification status [12]. ASA-I: completely healthy fit patient; ASAII: Patient
has mild systemic disease; ASA-III: severe systemic disease that is not incapacitating;
ASA-IV: Patient has incapacitating disease that is a constant threat to life; ASA-V: A
moribund patient who is not expected to live 24 hour with or without surgery.
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Desjardins Hôtel-Dieu de Lévis hospital (QC, Canada),
and was approved by the CSSS Alphonse-Desjardins
ethic committee with number # CER 1112–030.
Patients and treatment
Among the 11 patients diagnosed for critical CO-
poisoning based on their carboxyhemoglobin level upon
arrival at the emergency department of CSSS Alphonse-
Desjardins Hospital, 6 patients ≥ 18 years were included
in the present study as they completed the entire drug
treatment and HBO protocol described below. All pa-
tients were administered rocuronium bromide (Mckesson,
Québec, Canada) to allow proper intubation before being
placed in the pressure chamber, propofol (Mckesson,
Québec, Canada) to provide sedation, and then were
treated with HBO according to a protocol adapted from
that of Weaver et al., [6]. This included 3 HBO treat-
ments called HBOT1, HBOT2, and HBOT3 at a pres-
sure of 2.5 to 2.8 atmospheres absolute (ATA) within
24 hours. During each HBOT, the patients were given
100 vol% oxygen for 3 periods of 30 minute duration as
well as ambient air for 2 periods of 10 minute duration
between each oxygen period. In-between the HBOTs,
the sedated patients were brought back to the intensive
care unit; there was no need for transportation of the
sedated patients from the ICU to the pressure chamber
in-between the HBO-treatments. All along their treat-
ment in the pressure chamber and the intensive care unit,
the patients were maintained intubated and sedated at a
score of 5–6 on the Ramsay scale by administering
rocuronium bromide and propofol repeatedly.
Based on clinical assessment, additional pharmaco-
logical treatments were given during the 24-h HBO/
ICU period: Patient #3 was administered a single injec-
tion of 0.05 mg fentanyl before HBOT1 in addition of
propofol; Patient #1 and Patient #5 were given ventolin®;
Patient #1, Patient #3, and Patient #4 were given water-
soluble vitamin B1 (thiamin). Also, Patient #3 and
Patient #4 were given one additional HBOT. No cat-
echolamine was given.
Data collection & outcome measures
One investigator reviewed and abstracted the data
from the medical records. Demographic information,
CO-poisoning history, comorbidities, blood gas mea-
surements, and sedation protocol were extracted. The
patients’ hemodynamic profile comprising heart rate
(HR), systolic blood pressure (SBP) and diastolic blood
pressure (DBP) were also reviewed. Values measured
from one of the patients’ arm using an Oscill Mate
1630 automated device (CASMED® Inc., Branford, CT,
USA) were recorded every five minutes and averaged
to obtain mean value during HBOT1, HBOT2, andHBOT3. Also, pulse blood pressure (ΔBP) was further
assessed by calculating the difference between SBP and
DBP.
Data analysis
Data are expressed as the median value and the 25th
and 75th percentiles, and analyzed using non-parametric
methods with the SAS 9.2 software (SAS Institute, Cary,
NC, USA). Within-group comparisons between HBOT
were performed using the Friedman analysis of variance;
following a significant F value, post hoc comparisons
were made using the Wilcoxon t-test (two-tailed). The
statistical significance was set at α = 5%.
Results
Patients were 4 males and 2 females of 36 to 63 years of
age. Four CO-poisonings were intentional and two were
declared accidental. Three cases were related to fire smoke
inhalation. Individual detailed demographic information,
CO-poisoning history, and comorbidities are given in
Table 1.
We examined the effects of HBOT on the hemodynamic
parameters of these CO-poisoned patients. We found that
HR increased significantly as the number of HBOT in-
creased from 68 beats per minute (bpm) during HBOT1
to 77 and 86 bpm during HBOT2 and HBOT3, respect-
ively (F = 7, p < 0.05). This resulted in a trend toward in-
crease in HR between HBOT1 and HBOT2 (T = 1.892,
p < 0.1) that reached statistical significance between
HBOT1 and HBOT3 (T = 2.207, p < 0.05). SBP showed
significant changes across treatments from 102 mmHg
during HBOT1 to 130 and 112 mmHg during HBOT2
and HBOT3, respectively (F = 8.333, p < 0.02). This led
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HBOT2 (T = 2.201, p < 0.05) but not between HBOT1
and HBOT3 (T = 1.153). In addition, ΔBP also showed
significant changes across treatments from 44 mmHg
during HBOT1 to 58 and 49 mmHg during HBOT2 and
HBOT3, respectively (F = 9.250, p = 0.01). This resulted
in a significant difference in ΔBP between HBOT1 and
HBOT2 (T = 2.214, p < 0.05), but not between HBOT1
and HBOT3 (T = 1.577). In contrast with HR, DBP and
ΔBP, no significant change was found for DBP (F = 0.882).
Individual data of HR, SBP, DBP, and ΔBP are shown in
Table 2.
Discussion and conclusions
In this retrospective study performed in critically ill CO-
poisoned patients treated with rocuronium bromide,
propofol, and HBO, we observed both a sustained
increase in HR and a transient increase in SBP and ΔBP.
In contrast with these effects, previous hemodynamic
anesthesia studies have reported no or little vagolytic
effects of rocuronium bromide alone on HR, SBP, and
DPB [13-15]. Also, in contrast with these effects and the
findings of the present report, propofol has been demon-
strated in other anesthesia studies to produce marked
decreases in HR, SBP and DBP [16-18]. Likewise, HBO
studies in healthy subjects, non-CO-poisoned patients
and laboratory animals have also reported marked
decreases in HR [7-11], SBP and DBP [7], as a conse-
quence of hyperbaric oxygen rather than increased
pressure per se [7]. In contrast with these effects of
rocuronium bromide, propofol and HBO, acute CO-
poisoning with carboxyhemoglobin values above 25%
has been commonly reported to increase HR [19,20] as
well as, in a more controversial fashion, both SBP and





Patient HBOT1 HBOT2 HBOT3 HBOT1 HBOT2 HBOT
#1 70 73 75 101 129 142
#2 63 76 66 93 114 108
#3 71 68 74 99 113 109
#4 87 103 97 104 134 115
#5 67 78 100 125 131 107
#6 61 83 111 134 147 143
Median 69 77 86*† 103 130* 112†
Q1 64 74 74 100 118 108
Q3 71 82 99 120 133 135
Individual data, and median and quartiles values of heart rate (HR), systolic blood p
during HBOT1, HBOT2, and HBOT3. Patients #1 and #6 suffered coronary artery dise
indicating so far as SBP and ΔBP are concerned that HBOT3 values had not return t
calculating the mean of the 26 values recorded every 5 minutes during HBOT1, HBOcould appear as a good candidate to explain our find-
ings; however, why these CO effects, if such, increased
across treatments i.e. showed long-lasting effects des-
pite HBO therapy is a question that still remains to be
elucidated. Based on a previous study that has reported
that most of the myocardial dysfunction as evaluated
using cardiac biomarkers and ejection fraction mea-
surements (but not hemodynamic parameters) dissi-
pates at 24 hours in CO-poisoned patients [21], it
could be hypothesized that adverse interactions be-
tween rocuronium bromide, propofol, HBO, and/or
CO could be responsible for the increase in HR, SBP,
and ΔBP observed in the present study. However, the
individual effects of rocuronium bromide, propofol,
and HBO – which all decrease HR, SBP and DBP when
given alone – clearly question such a possibility. With no
doubt, only a randomized controlled trial adequately
designed would be able to identify the actual contribution,
if any, of rocuronium bromide, propofol, and/or HBO in
the results observed.
Thus, if one assumes that the sustained increase in
HR from HBOT1 to HBOT3 as well as the transient
increase in SBP and ΔBP from HBOT1 to HBOT2
reported herein are the consequence of CO poisoning,
then the decrease in SBP and ΔBP recorded between
HBOT2 and HBOT3 could be viewed as a beneficial ef-
fect of HBO, which after detoxifying hemoglobin could
allow initiating the detoxification of other hemoproteins
such as myoglobin whose normal functioning is known
to be necessary for effective cardiac output. However,
although both SBP and ΔBP showed a general trend to-
ward reduction between HBOT2 and HBOT3, which
could indicate as suggested above that HBO had begun
to produce its beneficial effects, a careful examination




3 HBOT1 HBOT2 HBOT3 HBOT1 HBOT2 HBOT3
61 74 75 40 54 66
56 60 59 37 54 49
60 59 59 39 54 49
55 68 66 49 66 48
76 69 59 49 62 48
67 65 69 67 82 74
61 67 63 45 58* 49†
57 61 59 39 54 48
66 69 68 49 65 62
ressure (SBP), diastolic blood pressure (DBP) and pulse blood pressure (ΔBP)
ase and hypertension, respectively. * : p < 0.05 vs HBOT1. † : p = n.s. vs HBOT2,
o HBOT1 values. Individual data of HR, SBP, and DBP were obtained by
T2, and HBOT3.
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and coronary artery disease) still exhibited borderline
hemodynamic responses [22-27], with a SBP increase
above 140 mmHg and a ΔBP increase near or above
80 mmHg. Taken together with the sustained increase in
HR recorded from HBOT1 to HBOT3, these data suggest
that the detoxification of myoglobin by HBO could be
longer than generally thought, and that more 3 HBOT
sessions could be necessary to allow full hemodynamic
recovery in CO-poisoned patients or at least some of
them.
As the vast majority of the retrospective case-series
studies, the present report should be interpreted carefully
because of its inherited limitations. This includes the small
sample of patients, the lack of information on the duration
of the exposure to CO, the uncontrolled delay between
the end of the exposure to CO and the first HBOT session,
the uncontrolled administration of medication, and the
absence of actual post-treatment evaluations that could
have indicated that HR, SBP, and ΔBP had finally returned
to basal values. However, despite these limitations, we
believe that the present study is of actual interest since it
is the first one, to the best of our knowledge, to report the
hemodynamic effects of HBO in critically ill CO-poisoned
patients.
Given the respective effects of rocuronium bromide,
propofol, HBO, and CO on the hemodynamic parameters,
we conclude as discussed in details above that the increase
in HR, SBP and ΔBP observed in the present study is likely
to be due to CO, and that more than 3 HBO sessions
would be necessary to provide full hemodynamic recovery
in CO-poisoned patients. If such, it is likely that HR, SBP,
and ΔBP could be used as physiological markers to assess
CO detoxification. Monitoring these hemodynamic pa-
rameters together with patient outcomes in future pro-
spective clinical studies could document this possibility.
With no doubt, further studies are needed to confirm our
hypothesis, and lead clinicians to use hemodynamic
parameters as a clinical biomarker for CO-poisoning
and HBO detoxification.Consent
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